地西他滨联合IAG/DAG治疗急性髓系白血病的临床疗效

目的 探讨地西他滨（DAC）联合IAG/DAG治疗急性髓系白血病（AML）的临床疗效与安全性。方法 选取2017年6月至2019年12月安徽医科大学第一附属医院血液科收治的23例初治或复发AML患者，采用DAC联合IAG/DAG诱导治疗，统计分析临床疗效及安全性。结果 23例患者均予以DAC联合IAG/DAG诱导化疗，其中完全缓解13例，部分缓解2例，总有效率为65.22%。23例患者均出现Ⅲ～Ⅳ级的粒细胞和血小板减少，1例患者因严重脑出血死亡。结论 DAC联合IAG/DAG治疗AML临床疗效较好，且不良反应可耐受，安全性高，值得临床推广应用。

Therapeutic effect of decitabine combined with reduced IAG/DAG on acute myeloid leukemia

Objective To observe the clinical efficacy and safety of decitabine combined with IAG/DAG in the treatment of acute myeloid leukemia(AML). Methods Twenty-three patients with AML admitted from June 2017 to December 2019 were treated with decitabine combined with IAG/DAG. The clinical efficacy and safety were evaluated. Results All 23 patients received decitabine combined with IAG/DAG induction chemotherapy.Among them,13 patients achieved complete remission,2 patients achieved partial remission, and the overall response rate was 65.22%.All patients had grade III~IV neutropenia and thrombocytopenia, and one patient died of severe cerebral hemorrhage. Non-hematologic toxicity such as gastrointestinal reactions, liver function damage and infection were controllable. Conclusions Decitabine combined with IAG/DAG for AML has good clinical efficacy, tolerable adverse reactions, and high safety, thus it is worth clinical promotion and application for poor physical performance patients.